Several other equities research analysts have also recently commented on the stock. Chardan Capital set a $6.00 price target on shares of Mesoblast and gave the stock a hold rating in a research report on Friday, August 30th. HC Wainwright set a $7.00 price target on shares of Mesoblast and gave the stock a buy rating in a research report on Friday, August 30th. Zacks Investment Research cut shares of Mesoblast from a buy rating to a hold rating in a research report on Friday, September 6th. Finally, Maxim Group reiterated a buy rating and set a $16.00 price target on shares of Mesoblast in a research report on Wednesday, June 12th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $11.25.
Shares of NASDAQ MESO traded up $0.43 during trading on Tuesday, reaching $7.18. The company had a trading volume of 3,921 shares, compared to its average volume of 43,361. Mesoblast has a 52 week low of $3.35 and a 52 week high of $8.78. The stock has a market cap of $572.56 million, a PE ratio of -7.91 and a beta of 1.77. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.92 and a current ratio of 1.41. The business’s 50 day moving average price is $5.06 and its 200-day moving average price is $5.09.
An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley boosted its position in shares of Mesoblast limited (NASDAQ:MESO) by 284.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 147,702 shares of the company’s stock after purchasing an additional 109,295 shares during the quarter. Morgan Stanley owned 0.16% of Mesoblast worth $784,000 as of its most recent SEC filing. 2.76% of the stock is currently owned by institutional investors and hedge funds.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.